NASDAQ: TTNP stock at https://www.webull.com/quote/nasdaq-ttnp today announced its fourth quarter and total year 2019 financial results will be released after market close on Monday, March 30, 2020.
Titan may host a live conference call to discuss the financial results and offer an overall small business review precisely the identical afternoon, March 30, 2020, at 4:30 p.m. ET / 1:30 p.m. PT. An overview of the fourth quarter and full-year financial results along with other highlights will be contained in a media release to be issued before the telephone.TTNP stock’s commercial surgeries expansion has lasted during the last few years, together with additions to its earnings and health liaison teams, for example support from other medical and marketing care employees that currently offer coverage for all 50 states and Puerto Rico.
The live webcast and a replay of this call can be obtained by seeing http://www.titanpharm.com/news/events. The call may also be obtained by dialing 1-888-317-6003 (or even 1-412-317-6061 from beyond the U.S.) ten minutes before the beginning period and supplying passcode 2248161.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP stock), located in South San Francisco, CA, is currently an industrial platform company developing proprietary therapeutics using its ProNeura® long term, constant drug delivery technologies. The organization’s lead product is Probuphine® (buprenorphine) enhancement, a publication and long-acting formula of buprenorphine for its long term care treatment of opioid addiction. Accepted by the U.S. Food and Drug Administration in May 2016, Probuphine is your very first and just real treatment of opioid addiction to present constant, high blood levels of buprenorphine for 2 months after a single process. The ProNeura technology can be utilized in creating products for treating other chronic illnesses like Parkinson’s disease and migraines, in which preserving constant, high blood levels of drugs may help the individual and enhance clinical consequences. To learn more regarding Titan, please see www.titanpharm.com.
Such statements include, but aren’t restricted to any statements concerning our product development applications and some other statements which aren’t historical facts. Such statements involve uncertainties and risks which could adversely impact our business, operating results, financial condition, and stock price. Factors that strength cause actual consequences to vary substantially from management’s existing expectations include those risks and doubts about the commercialization of Probuphine; the regulatory approval process; Titan’s capacity to get funding; the creation, testing, creation, and promotion of the drug candidates; patent and intellectual property issues; and tactical arrangements and associations. We openly reject any obligation or undertaking to release publicly any informs or adjustments to approximately forward-looking declarations comprised herein to reproduce any change in our expectations or any changes in events, conditions or circumstances on which any statement is based, except as required by legislation. You can also check qqq news at https://www.webull.com/quote/nasdaq-qqq .